Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Clinical trial NCT02226172 · TERMINATED

Trial details

NCT number: NCT02226172
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Start date: 2014-10-06
Primary completion: 2016-12-14
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.